As Eli Lilly (LLY) becomes the first pharmaceutical company to hit $1T in market cap, Seeking Alpha takes a look at some of the best Quant-rated mid-to-small-cap healthcare stocks.
In today’s volatile market, investors are constantly searching for stocks with strong growth potential and solid financial fundamentals. These companies are still under $7B in market cap but have been rated “Strong Buy” by Seeking Alpha’s Quant rating system.
The stocks featured in this list have been filtered through Seeking Alpha’s proprietary Quant Model. This sophisticated trading algorithm evaluates stocks based on multiple factors, including growth, profitability, value, momentum, and rising analysts’ earnings estimates.
The model has proven remarkably effective, with Seeking Alpha’s very bullish Quant Stock recommendations outperforming the S&P 500 (SP500) by 1,755% versus 379% from January 2010 to June 2021.
Top small-cap and mid-cap healthcare stocks by Quant:
- Inhibrx Biosciences (INBX) – Strong Buy rating (4.99), up 108.90% year-to-date, $1.16B market cap
- Nektar Therapeutics (NKTR) – Strong Buy rating (4.98), up 434.71% year-to-date, $1.12B market cap
- GRAIL, Inc. (GRAL) – Strong Buy rating (4.97), up 117.83% year-to-date, $3.34B market cap
- Zenas BioPharma (ZBIO) – Strong Buy rating (4.95), up 203.48% year-to-date, $1.87B market cap
- PTC Therapeutics (PTCT) – Strong Buy rating (4.91), up 61.99% year-to-date, $6.14B market cap
- Amylyx Pharmaceuticals (AMLX) – Strong Buy rating (4.91), up 145.83% year-to-date, $1.49B market cap
- Arcus Biosciences (RCUS) – Strong Buy rating (4.89), up 139.35% year-to-date, $2.29B market cap
- TG Therapeutics (TGTX) – Strong Buy rating (4.89), down 14.15% year-to-date, $4.45B market cap
- Sight Sciences (SGHT) – Strong Buy rating (4.88), up 103.06% year-to-date, $351.07M market cap
- AnaptysBio (ANAB) – Strong Buy rating (4.87), up 78.48% year-to-date, $1.04B market cap